Alisar Pharma

Alisar Pharma is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutics for immune-mediated inflammatory diseases. The company's primary focus is on its lead asset, ALR-101, a selective covalent inhibitor of Janus kinase 3 (JAK3) and TEC family kinases. By targeting these specific pathways, Alisar aims to treat conditions such as alopecia areata, psoriasis, and atopic dermatitis with improved selectivity and reduced off-target effects compared to first-generation JAK inhibitors. The company is led by a team of experienced drug developers and is headquartered in the San Francisco Bay Area. Its approach leverages covalent chemistry to achieve durable inhibition and high potency in treating autoimmune disorders.